InflaRx (IFRX) Interest Income - Total (2017 - 2026)
InflaRx's (IFRX) quarterly Interest Income - Total came in at $4.2 million in Q2 2026, up 146.55% year-over-year from $1.7 million in Q2 2025, and up 321.09% quarter-over-quarter from -$1.9 million in Q1 2026.
Analysis
InflaRx (IFRX) Interest Income - Total (2017 - 2026) Analysis & Trends
InflaRx has disclosed Interest Income - Total across 9 years of filings, most recently posting $4.2 million for Q2 2026.
- In Q2 2026, Interest Income - Total rose 146.55% year-over-year to $4.2 million; the TTM figure through Jun 2026 stood at $3.0 million (up 149.83% YoY), while the FY2025 annual figure was -$3.0 million, up 59.87% from the prior year.
- Interest Income - Total came in at $4.2 million for Q2 2026 at InflaRx, up from -$1.9 million in the prior quarter.
- In the past five years, Interest Income - Total ranged from a high of $4.2 million in Q2 2026 to a low of -$5.0 million in Q4 2024.
- Average Interest Income - Total over 5 years is -$730977.4, with a median of -$1.3 million recorded in 2022.
- Year-over-year, Interest Income - Total soared 744.55% in 2023 and slumped 686.06% in 2024.
- Over 5 years, Interest Income - Total stood at $334283.0 in 2022, then soared by 744.55% to $2.8 million in 2023, then tumbled by 276.07% to -$5.0 million in 2024, then soared by 48.09% to -$2.6 million in 2025, then surged by 262.04% to $4.2 million in 2026.
- Per Business Quant data, the three most recent Interest Income - Total figures were $4.2 million in Q2 2026, -$1.9 million in Q1 2026, and -$2.6 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Income - Total (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | InflaRx | 139.29 Mn | -44.96 Mn | 2.74 Mn | 4.18 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 4.18 Mn |
| Jun 30, 2026 | 4.18 Mn |
| Mar 31, 2026 | -1.89 Mn |
| Mar 31, 2026 | -1.89 Mn |
| Dec 31, 2025 | -2.58 Mn |
| Dec 31, 2025 | -2.58 Mn |
| Sep 30, 2025 | 3.24 Mn |
| Sep 30, 2025 | 3.24 Mn |
| Jun 30, 2025 | 1.70 Mn |
| Jun 30, 2025 | 1.70 Mn |
| Mar 31, 2025 | -4.93 Mn |
| Mar 31, 2025 | -4.93 Mn |
| Dec 31, 2024 | -4.97 Mn |
| Dec 31, 2024 | -4.97 Mn |
| Sep 30, 2024 | 2.29 Mn |
| Sep 30, 2024 | 2.29 Mn |
| Jun 30, 2024 | -1.67 Mn |
| Jun 30, 2024 | -1.67 Mn |
| Mar 31, 2024 | -3.08 Mn |
| Mar 31, 2024 | -3.08 Mn |